论文部分内容阅读
乙型肝炎病毒大约已发现有20年、甲型肝炎病毒大约发现有15年,这以后尽管做了许多努力也没有弄清非甲非乙型肝炎病毒的实质。近年又发现C型肝炎病毒(HCV)。本文仅就至今为止所观察的对非甲非乙型肝炎,用因他非龙治疗的临床效果和于扰索对新发现的HCV病毒的抗病毒作用加以阐述。一、非甲非乙型肝炎的临床经过综合临床研究概括如下: 1.发病原因40%是由输血而来,其他60%是不明途径的感染; 2.输血后患肝炎的发病率为20%,其中至少半数是慢性肝炎; 3.慢性肝炎约经过20年可变成肝硬化、肝癌,但是还不清楚其中多少变为肝硬化,多少变为肝癌。肝癌患者40%有输血史,然而重新测定抗HCV抗
Hepatitis B virus has been found for about 20 years and Hepatitis A virus has been found for about 15 years. Since then, the substance of non-A, non-Hepatitis B virus has not been clarified despite much effort. Hepatitis C virus (HCV) has also been found in recent years. This article describes the antiviral effects of the newly discovered HCV virus only on the clinical effects of non-dragine therapy and on the interference scans of non-A, non-B hepatitis observed so far. First, non-A non-Hepatitis B clinical clinical research summarized by the following: 1. Causes 40% of transfusions come from, the other 60% is an unknown pathological infection; 2. The incidence of hepatitis after blood transfusion was 20% Of which at least half are chronic hepatitis; 3. Chronic hepatitis cirrhosis, liver cancer after about 20 years, but it is still not clear how many of them become cirrhosis, how many become liver cancer. 40% of patients with liver cancer have a history of blood transfusions, however, retest anti-HCV anti-HCV